

Certification of Substances Department

Certificate of suitability
No. R0-CEP 2018-135-Rev 00

1 *Name of the substance:*

2 **BOVINE PERICARDIAL TISSUE**

3 *Name of holder:*

4 **TISSX INC**

5 3405 Annapolis Lane

6 Suite 200

7 United States Am.-55447 Plymouth, Minnesota

8 *Site(s) of production:*

9 **TISSX INC**

10 3405 Annapolis Lane

11 Suite 200

12 United States Am.-55447 Plymouth, Minnesota

13 After examination of the information provided on the origin of raw material(s) and type of tissue(s)
14 used and on the manufacturing process for this substance on the site(s) of production mentioned
15 above, we certify that the substance **BOVINE PERICARDIAL TISSUE** meets the criteria
16 described in the current version of the monograph Products with risk of transmitting agents of
17 animal spongiform encephalopathies no. 1483 of the European Pharmacopoeia, current edition
18 including supplements.

19 – Country of origin of source materials:

20 United States of America

21 – Nature of animal tissues used in manufacture:

22 Bovine Pericardium

23 The submitted dossier must be updated after any significant change that may alter the quality,
24 safety or efficacy of the substance, or that may alter the risk of transmitting animal spongiform
25 encephalopathy agents.

26 Manufacture of the substance shall take place in accordance with a suitable quality assurance
27 system, and in accordance with the dossier submitted.

28 Failure to comply with these provisions will render this certificate void.

29 The certificate is valid provided that there has been no deterioration in the TSE status of the
30 country(ies) of origin of the source material.

Address: 7 Allée Kastner, CS 30026


F-67081 Strasbourg (France)

Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu

Internet: <http://www.edqm.eu>

31 This certificate is granted within the framework of the procedure established by the European
32 Pharmacopoeia Commission [Resolution AP-CSP (07) 1] for a period of five years starting from
33 **6 March 2019**. Moreover, it is granted according to the provisions of Directive 2001/83/EC and
34 Directive 2001/82/EC and any subsequent amendment, and the related guidelines.

35 This certificate has:
36 lines.


On behalf of the
Director of EDQM



Strasbourg, 6 March 2019

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

TISSX INC, as holder of the certificate of suitability

R0-CEP 2018-135-Rev 00 for Bovine pericardial tissue

hereby authorises
(name of the pharmaceutical company)

to use the above-mentioned certificate of suitability in support of their application(s) for the following
Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

The holder also certifies that no significant changes to the operations as described in the CEP dossier
have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*: